The reason why stem cell index was not statistically significant for survival might be due to the fact that patients with higher mRNAsi, such as TNBC, generally lacked therapeutic target, while other BC subtypes had more specific treatment strategies, such as Herceptin and other targeted drugs for HER-2-positive patients and, etc [29, 30]. The gene discussed is ERBB2; the disease is breast cancer.